Effects of statin therapy on arterial stiffness: A systematic review and meta-analysis of randomized controlled trial

International Journal of Cardiology

Volumn 227, Issue , 2017, Pages 338-341

  Upala, Sikarin ^a,b   Wirunsawanya, Kamonkiat ^c   Jaruvongvanich, Veeravich ^c,d   Sanguankeo, Anawin ^a,b  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF HAWAII   (United States)

^d KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

Arterial stiffness; Lipid lowering therapy; Meta analysis; Pulse wave velocity; Statin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

AORTIC PULSE WAVE VELOCITY; ARTERIAL STIFFNESS; ARTICLE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; SYSTEMATIC REVIEW; DRUG EFFECTS;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PULSE WAVE ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR STIFFNESS;

EID: 85003899042     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.11.073     Document Type: Article

References (24)

1. [1] Zieman, S.J., Melenovsky, V., Kass, D.A., Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 25 (2005), 932–943.
2. [2] Cavalcante, J.L., Lima, J.A., Redheuil, A., et al. Aortic stiffness: current understanding and future directions. J. Am. Coll. Cardiol. 57 (2011), 1511–1522.
3. [3] Cohn, J.N., Arterial stiffness, vascular disease, and risk of cardiovascular events. Circulation 113 (2006), 601–603.
4. [4] Rizos, E.C., Agouridis, A.P., Elisaf, M.S., The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr. Vasc. Pharmacol. 8 (2010), 638–644.
5. [5] Mitchell, G.F., Hwang, S.J., Vasan, R.S., et al. Arterial stiffness and cardiovascular events: the Framingham heart study. Circulation 121 (2010), 505–511.
6. [6] Moher, D., Pham, B., Jones, A., et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 352 (1998), 609–613.
7. [7] Higgins, J.P., Thompson, S.G., Deeks, J.J., et al. Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
8. [8] Sterne, J.A., Egger, M., Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J. Clin. Epidemiol. 54 (2001), 1046–1055.
9. [9] Pirro, M., Schillaci, G., Mannarino, M.R., et al. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. Nutr. Metab. Cardiovasc. Dis. 17 (2007), 436–441.
10. [10] Orr, J.S., Dengo, A.L., Rivero, J.M., et al. Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension 54 (2009), 763–768.
11. [11] Wallace, S.M., Maki-Petaja, K.M., Cheriyan, J., et al. Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction. Br. J. Clin. Pharmacol. 70 (2010), 799–806.
12. [12] Lunder, M., Janic, M., Habjan, S., et al. Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males—a pilot study. Atherosclerosis 215 (2011), 446–451.
13. [13] Kanaki, A.I., Sarafidis, P.A., Georgianos, P.I., et al. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am. J. Hypertens. 26 (2013), 608–616.
14. [14] Oh, P.C., Han, S.H., Koh, K.K., et al. Rosuvastatin treatment improves arterial stiffness with lowering blood pressure in healthy hypercholesterolemic patients. Int. J. Cardiol. 176 (2014), 1284–1287.
15. [15] Benetos, A., Safar, M., Rudnichi, A., et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 30 (1997), 1410–1415.
16. [16] Chae, C.U., Pfeffer, M.A., Glynn, R.J., et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA 281 (1999), 634–639.
17. [17] Vaccarino, V., Berger, A.K., Abramson, J., et al. Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program. Am. J. Cardiol. 88 (2001), 980–986.
18. [18] Ikdahl, E., Rollefstad, S., Hisdal, J., et al. Sustained improvement of arterial stiffness and blood pressure after long-term rosuvastatin treatment in patients with inflammatory joint diseases: results from the RORA-AS study. PLoS One, 11, 2016, e0153440.
19. [19] O'Rourke, M., Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension. Hypertension 15 (1990), 339–347.
20. [20] Laufs, U., La Fata, V., Plutzky, J., et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998), 1129–1135.
21. [21] Rosenson, R.S., Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 173 (2004), 1–12.
22. [22] Sicard, P., Lauzier, B., Oudot, A., et al. A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats. Arch. Mal. Coeur Vaiss. 98 (2005), 804–808.
23. [23] Gao, L., Wang, W., Li, Y.L., et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 112 (2005), 1763–1770.
24. [24] Gao, L., Wang, W., Zucker, I.H., Simvastatin inhibits central sympathetic outflow in heart failure by a nitric-oxide synthase mechanism. J. Pharmacol. Exp. Ther. 326 (2008), 278–285.